Top Players and Market Competition in the Sartans Industry

The sartans market is poised for consistent expansion over the coming years, driven by a combination of demographic shifts and evolving healthcare needs. As the prevalence of chronic conditions rises, the demand for effective and affordable sartans therapies continues to grow, setting the stage for notable market progress through 2030.

Projected Growth and Size of the Sartans Market by 2030
The sartans market is anticipated to reach a valuation of $27.14 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.1%. This upward trajectory is supported by factors such as an aging global population, increasing cases of kidney disease, the rising preference for cost-efficient treatments, a broader adoption of outpatient care, and the expansion of digital pharmacy platforms. Additional market drivers include enhanced applications in managing hypertension, the rising prominence of generic angiotensin receptor blockers, a growing inclination toward combination therapies for cardiovascular conditions, and an emphasis on products that provide renal and cardiovascular protection.

Download a free sample of the sartans market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24393&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Factors Fueling Sartans Market Expansion
One of the main contributors to the growth of the sartans market is the expanding elderly population, which is more prone to hypertension and related cardiovascular issues requiring sartans for management. Alongside this demographic trend, there is a notable increase in kidney disease cases globally, further boosting the need for effective medication options within this drug class.

In addition, the healthcare industry's shift towards more affordable treatment alternatives supports the adoption of generic sartans, making therapies more accessible to a wider patient base. The rise of outpatient care models and digital pharmacies also facilitates easier distribution and access to sartans, reinforcing market growth during the forecast period.

View the full sartans market report:
https://www.thebusinessresearchcompany.com/report/sartans-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Corporations Driving Innovation in the Sartans Market
The sartans sector is dominated by several prominent pharmaceutical companies, including Viatris Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cadila Pharmaceuticals Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Unichem Laboratories Ltd., Emcure Pharmaceuticals Ltd., Mylan N.V., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Ltd., Abbott Laboratories, Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Bayer AG, and Merck & Co. Inc.

Noteworthy Collaborations and Product Launches in Sartans
In April 2025, Scienture Holdings, Inc., a US-based manufacturer specializing in sartans, forged a partnership with Saptalis Pharmaceuticals to produce Arbli, a losartan potassium oral suspension (10 mg/mL). This collaboration also includes warehousing and distribution agreements with strategic partners to ensure ready market access for the first FDA-approved ready-to-use oral liquid losartan. This product aims to meet previously unaddressed needs in hypertension treatment. Saptalis Pharmaceuticals is also based in the United States.

Current Trends Highlighting Opportunities in the Sartans Market
Pharmaceutical companies in the sartans space are focusing on developing advanced formulations like tablet-form sartans to boost treatment effectiveness and improve patient compliance. These oral medications work by blocking angiotensin II's effects, which relaxes blood vessels and lowers blood pressure.

For example, in July 2024, India-based Zydus Lifesciences received FDA approval for Valsartan Tablets USP (available in 40 mg and 80 mg strengths). Marketed under the brand name Diovan, these tablets are prescribed for managing hypertension, heart failure, and improving survival rates after heart attacks in adults. They are also suitable for pediatric patients aged one year and older, broadening their therapeutic reach.

Breakdown of Sartans Market Segments by Product, Distribution, and Application
The sartans market is categorized into multiple key segments:
1) Product Type: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
2) Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
3) Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications
4) End-User: Hospitals, Other End-Users

Further subsegments for each product type include a variety of dosage forms and delivery methods. For instance, Valsartan is available as film-coated tablets, oral powder sachets, triple-combination tablets, and ready-to-use liquid formulations. Telmisartan comes in soft gel capsules, mouth-dissolving strips, sustained-release tablets, and sachet-packed granules. Losartan is offered as chewable tablets, pediatric oral drops, effervescent tablets, and dispersible tablets. Irbesartan includes high-potency tablets, scored tablets, hospital bulk packs, and blister strip packs. Azilsartan is available in nanoparticle-based tablets, rapid-onset tablets, unit-dose capsules, and microgranule sachets. Lastly, Olmesartan formulations include oral jelly, oral thin films, powder-for-suspension packs, and dual-layer tablets.

Geographical and Market Expansion Insights
Though specific regional market shares are not detailed here, growth prospects are influenced by rising disease prevalence, healthcare infrastructure improvements, and increasing accessibility, which are expected to drive adoption across various global markets through 2030.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.